Actively Recruiting
Study of Alpha DaRT Seeds Implantation to Treat Non-Metastatic Locally Recurrent Prostate Cancer in Men
Led by Alpha Tau Medical LTD. · Updated on 2026-06-16
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility and safety of implanting intratumoral Diffusing Alpha Emitters Radiation Therapy DaRT seeds for treating men with non-metastatic locally recurrent prostate cancer. This prospective, multicenter, single-arm, open-label interventional study focuses on men with confirmed recurrent prostate adenocarcinoma confined to the prostate, aiming to assess how well the DaRT seeds can be placed and their impact on patient quality of life. Participants receive treatment through insertion of radioactive Ra-224 containing stainless steel tubes DaRT seeds directly into prostate tumors. The study primarily measures feasibility by the success rate of seed placement immediately after the procedure. Secondary objectives include evaluating patient-reported quality of life following treatment. This study enrolls up to 10 men and does not include a comparison group. During the study, participants undergo imaging to confirm seed placement and are monitored for safety and treatment effects. Researchers collect data on quality of life and perform assessments such as PSA levels and metastatic workups. Participants must meet eligibility criteria including specific lesion size, absence of metastases, and ability to undergo anesthesia. The study is expected to complete by June 2027, with ongoing observation after seed implantation.
CONDITIONS
Brief Title
Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.
Research Team
L
Liron Dimnik
A
Aviya Hoida
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here